Q3 2026 AbbVie Inc. Earnings Conference Call - LIFECELL CORP

Financial Performance:

• Reported Q3 2026 adjusted EPS of $3.82, beating guidance by $0.07.
• Total net revenues reached $17.4 billion (up 10.5% organically), exceeding expectations by $200 million.
• Nine key products delivered double-digit growth, including Skyrizi ($5.8B, +22.9%), Rinvoq ($2.7B, +24.3%), and Vraylar ($1.1B, +14.3%).
• Adjusted gross margin stood at 85.1%; adjusted operating margin was 48.7%.
• Generated $14 billion in free cash flow year-to-date, supporting a $1.82 quarterly dividend (5.2% increase).
• Cash balance was $10.8 billion at end of September; net leverage target of 2.0x is on track over 2–3 years post-Apogee acquisition.

Guidance and Future Outlook:

• Raised full-year adjusted EPS guidance midpoint to $13.97 (range $13.95–$13.99) and total revenue to $67.8 billion.
• Q4 2026 revenue guidance set at approximately $18.4 billion; adjusted EPS guidance $3.83–$3.87.
• 2027 guidance to be provided in the Q4 call; management expects 2026 to be the second-highest growth year vs. peers.
• Forecasted 2026 operating margin of 46.7% (including ~1.8% unfavorable IPR&D impact); FY2027 guidance assumes similar margin discipline.
• Long-term revenue outlook for 2030s supported by strong pipeline and existing franchises (Immunology, Neuroscience, Oncology).

Business Segments and Product Lines:

• Immunology: Skyriziz total sales $5.8B (+22.9%); Rinvoq $2.7B (+24.3%). Humira sales $683M (-30.6%) due to biosimilars.
• Neuroscience: Revenues $3.4B (+19.5%). Launched Juvemo (Parkinson's); Vylev and Duopa expected to reach $5B+ peak sales collectively. Vraylar driving growth in psychiatry.
• Oncology: Total revenues $1.7B (+0.9%). Van Clexta (+10.7%) and Epkinley offsets Imbruvica decline (-26.1%). Etentamig application submitted for multiple myeloma; Epkinley Phase III data positive for frontline DLBCL.
• Aesthetics: Revenues $1.2B (-1.8%); Botox Cosmetic +4.1% driven by market growth, Juvederm -11.8% due to market headwinds.
• R&D Milestones: FDA approved Skyrizi sub-Q induction for Crohn's; Apogee Therapeutics acquisition completed; Juvemo approved for Parkinson's; Etentamig and Epkinley regulatory submissions anticipated in 2027; QLIPTA and Ubrelvi data for menstrual migraine.

Market and Competitive Landscape:

• Skyrizi and Rinvoq continue to gain share despite competition; Skyrizi captures ~50% of new starts in IBD and Psoriasis.
• Sub-Q induction for Skyrizi expected to accelerate Crohn's share; data shows superior endoscopic response vs. IV formulation.
• Neuroscience sector: AbbVie positioned as industry leader with 20% growth expected in 2026; new Juvemo entry targets D1/D5 receptors to avoid side effects of D2/D3 agonists.
• Aesthetics market showing signs of stabilization; new fast-acting toxin (BOE) in Europe/Canada receiving high patient satisfaction.
• Obesity pipeline: Amylin analog ABBV295 showing promising weight loss; company exploring combinations and potential external GLP-1 assets.

Risks and Challenges:

• Biosimilars: Continued erosion of Humira revenue ($683M Q3) due to biosimilar competition.
• Regulatory: BOE (Trinitybot E) CRL resubmission expected late 2026; FDA decision mid-2027.
• Policy/RP: IRA pricing impact on Imbruvica; ongoing 340B program challenges; Botox IRA eligibility under legal review (court ruled in favor regarding human serum albumin exclusion).
• Commercialization: Juvemo ramp dependent on Medicare coverage availability (likely 2028); new Rinvoq indications (Vitiligo, Alopecia) require market creation and investment.

Management Commentary and Tone:

• Tone is highly confident, emphasizing "outstanding results," "top-tier sales," and "above expectations" performance.
• Management highlights "excellent progress" in the pipeline and readiness to drive growth into the 2030s.
• Strong emphasis on capital allocation: dividend increases and capacity for bolt-on M&A in core areas (immunology, neuroscience, oncology, obesity).
• Confident in the ability to navigate competition and maintain market share despite increased rivalry in key categories.

Analyst Questions and Answers:

• 2027 Outlook & Payers: Rob Michael noted IRA pricing for Vraylar begins 2027; Jeff Stewart confirmed low single-digit rebate concessions for immunology and favorable access for new Rinvoq indications.
• Skyrizi Sub-Q Opportunity: Rupal Thakkar and Jeff Stewart highlighted superior endoscopic data for sub-Q induction; expected to accelerate share in first half of 2027.
• Pipeline Assets (Etenamig/Imraclidine): Rupal Thakkar identified Etenamig as a "multibillion" underappreciated asset with superior safety profile; Imraclidine moving to 150mg dose to improve PK/receptor occupancy.
• 340B & BOE: Rob Michael expressed support for 340B transparency pilot; Rupal confirmed BOE CRL resubmission late 2026.
• Obesity Strategy: Management indicated openness to GLP-1 assets for combination with amylin, prioritizing tolerability and efficacy differentiation.
• Juvemo Positioning: Early feedback suggests strong physician interest in sparing patients from Levodopa escalation; demand currently outpacing supply due to access hurdles.

Other Key Points:

• Acquired IPR&D expense from Apogee had an 11-cent unfavorable impact on Q3 adjusted EPS.
• Foreign exchange impact is estimated at -0.2% for Q3 and -0.5% for full year 2026.
• Pipeline expansion includes 8 distinct Phase III programs planned in immunology leading into the late 2020s/early 2030s.
• Epkinley partnership with Genmab results in profit-share revenue rather than full sales booking in US/Japan/Puerto Rico.
• Management expects to deliver top-tier growth again in 2027, driven by the "triple threat" of immunology, neuroscience, and oncology portfolios.